Subjects with Advanced or Metastatic Small Cell Lung Cancer

Status: open

17-080 - A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Pl

Treatment for Lung Cancer

Contact Us Or call (251) 445-9834


To assess if treatment with rovalpituzumab tesirine improves objective response rate (ORR) and overall survival (OS) compared to topotecan in subjects with advanced or metastatic DLL3high SCLC who have first disease progression during or following front-line platinum based chemotherapy.Therefore, exploration of new therapies in second line SCLC is warranted, with the goals of extending disease control and improving overall survival. IRB Number 17-080


This trial is sponsored by AbbVie.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.